Summary
GlobalData's clinical trial report, “Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Global Clinical Trials Review, H2, 2018" provides an overview of Granulomatosis with Polyangiitis (Wegener's Granulomatosis) clinical trials scenario. This report provides top line data relating to the clinical trials on Granulomatosis with Polyangiitis (Wegener's Granulomatosis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies Mentioned
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
ChemoCentryx Inc
Zenyaku Kogyo Co Ltd
Nippon Kayaku Co Ltd
AstraZeneca Plc
Arthritis Research UK
Anthera Pharmaceuticals Inc
AbbVie Inc
Abbott Laboratories
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Granulomatosis with Polyangiitis (Wegener's Granulomatosis) to Immunology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Granulomatosis with Polyangiitis (Wegener's Granulomatosis) to Immunology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 28
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials 33
Prominent Drugs 35
Clinical Trial Profile Snapshots 37
Appendix 95
Abbreviations 95
Definitions 95
Research Methodology 96
Secondary Research 96
About GlobalData 96
Contact Us 97
Source 97
List of Tables
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials by Region, 2018* 7
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 11
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 14
Proportion of Granulomatosis with Polyangiitis (Wegener's Granulomatosis) to Immunology Clinical Trials, G7 Countries (%), 2018* 16
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Granulomatosis with Polyangiitis (Wegener's Granulomatosis) to Immunology Clinical Trials, E7 Countries (%), 2018* 20
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials by Phase, 2018* 24
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 25
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 27
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 28
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 30
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
List of Figures
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 11
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 14
Proportion of Granulomatosis with Polyangiitis (Wegener's Granulomatosis) to Immunology Clinical Trials, G7 Countries (%), 2018* 15
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Granulomatosis with Polyangiitis (Wegener's Granulomatosis) to Immunology Clinical Trials, E7 Countries (%), 2018* 19
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 24
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 25
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 26
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 28
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 30
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 31
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 33
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 35
GlobalData Methodology 96
